表紙
市場調査レポート

PharmaPoint:C型肝炎市場−−ブラジルでの薬剤予測と市場分析

PharmaPoint: Hepatitis C Virus - Brazil Drug Forecast and Market Analysis to 2022

発行 GlobalData 商品コード 274252
出版日 ページ情報 英文 109 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
PharmaPoint:C型肝炎市場−−ブラジルでの薬剤予測と市場分析 PharmaPoint: Hepatitis C Virus - Brazil Drug Forecast and Market Analysis to 2022
出版日: 2013年05月31日 ページ情報: 英文 109 Pages
概要

当レポートでは、ブラジルにおけるC型肝炎(HVC)の治療薬に関する最新の研究・開発状況と、関連市場の将来展望とを分析し、疾患の概要や治療法、市場機会とアンメットニーズ、市場規模の動向(今後10年間分)、現在発売中および治験中の主な薬剤のプロファイル、米国市場の現状と今後の方向性などの情報を盛り込んで、概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因と病態
    • 病因
    • 病態
    • 予後
  • 兆候

第4章 疾患の管理

  • 診断・紹介の概要
  • 治療法の概要
  • ブラジル
    • 診断
    • 臨床診療

第5章 競争力の評価

  • 概要
  • 競合企業の戦略的評価
  • 製品プロファイル:主要ブランド
    • Incivek(テラプレビル)
    • Victrelis(ボセプレビル)
    • Pegasys(ペグインターフェロンα-2a)
    • PegIntron(ペグインターフェロンα-2a)
    • Copegus・Rebetol、および後発薬Ribavirin
    • 治療クラス:インターフェロン

第6章 市場機会とアンメットニーズ

  • 概要
  • アンメットニーズ
    • アンメットニーズ:薬剤耐性
    • アンメットニーズ:効能
    • アンメットニーズ:疾患の認知度
    • アンメットニーズ:治療費
    • アンメットニーズ:治療期間の短縮
    • アンメットニーズ:治療法の単純化
  • アンメットニーズのギャップの分析
  • 市場機会
    • 市場機会:全遺伝型のHCVウイルス向けの治療法
    • 市場機会:過小評価されてきた患者人口層への治療
    • 市場機会:免疫システムの関与

第7章 パイプライン分析

  • 概要
  • 治験中の有望な薬剤
    • Simeprevir
    • FaldaprevirおよびFaldaprevir+BI 207127
    • DaclatasvirおよびDaclatasvir+Asunaprevir
    • その他の薬剤クラス

第8章 市場の見通し

  • ブラジル市場
    • 予測
    • 主要動向
    • 促進要因と障壁

第9章 付録

図表一覧

目次
Product Code: GDHC1096CFR

Summary

GlobalData has released its new Country report, "PharmaPoint: Hepatitis C Virus - Brazil Drug Forecast and Market Analysis to 2022". Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing pegylated interferon (e.g., Roche's Pegasys and Merck's PegIntron) and ribavirin (e.g., Roche's Copegus and Merck's Rebetol) are used to treat HCV infection. Patients infected with HCV genotype 1 can also have a protease inhibitor added to their combination therapy, such as Merck's Victrelis (boceprevir) or Vertex's Incivek (telaprevir). The entrance of next-generation HCV therapies is expected to fundamentally change the HCV treatment algorithm. GlobalData expects a dramatic shift favoring the uptake of interferon-free regimens due to their more tolerable side-effect profiles and decreased duration of therapy compared with the current standard of care.

The anticipated drivers of growth of the HCV market in Brazil include increasing awareness of the disease, the adoption of non-invasive liver diagnostic tests, and the launch of next-generation HCV therapies.

Roche's Pegasys (peginterferon alfa-2a) is the current market leader in Brazil. Pegasys was launched in Brazil after Merck's PegIntron (peginterferon alfa-2b), but GlobalData believes that Pegasys was able to quickly dominate the market due to a perceived better side effect profile and efficacy. Sales of both Pegasys and PegIntron are projected to increase in Brazil as a result an increase in the country's HCV treatment rate. Sales of both drugs are also expected to be boosted by their drug's inclusion in triple therapies (i.e., DAA, peginterferon, and ribavirin).

Scope

  • Overview of the HCV including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in Brazil including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in Brazil from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting Brazil HCV market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for HCV
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in Brazil

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Diagnosis and Referral Overview
  • 4.2. Treatment Overview
  • 4.3. Brazil
    • 4.3.1. Diagnosis
    • 4.3.2. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment
  • 5.3. Product Profiles - Major Brands
    • 5.3.1. Incivek (telaprevir)
    • 5.3.2. Victrelis (boceprevir)
    • 5.3.3. Pegasys (peginterferon alfa-2a)
    • 5.3.4. PegIntron (peginterferon alfa-2b)
    • 5.3.5. Copegus, Rebetol, and Generic Ribavirin
    • 5.3.6. Therapeutic Class: Interferon

6. Opportunity and Unmet Need

  • 6.1. Overview
  • 6.2. Unmet Needs
    • 6.2.1. Unmet Need: Treatment Tolerability
    • 6.2.2. Unmet Need: Efficacy
    • 6.2.3. Unmet Need: Disease Awareness
    • 6.2.4. Unmet Need: Treatment Cost
    • 6.2.5. Unmet Need: Shorter Treatment Duration
    • 6.2.6. Unmet Need: Simplified Treatment Regimens
  • 6.3. Unmet Needs Gap Analysis
  • 6.4. Opportunities
    • 6.4.1. Opportunity: Pan-genotypic HCV Regimen
    • 6.4.2. Opportunity: Treatment of Underrepresented Patient Populations
    • 6.4.3. Opportunity: Involvement of Immune System

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development
    • 7.2.1. Simeprevir
    • 7.2.2. Faldaprevir and Faldaprevir plus BI 207127
    • 7.2.3. Daclatasvir and Daclatasvir plus Asunaprevir
    • 7.2.4. Other Drug Classes

8. Market Outlook

  • 8.1. Brazil
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Percent Drug-Treated Patients
    • 9.4.2. Patient Warehousing
    • 9.4.3. Drugs Included in Each Therapeutic Class
    • 9.4.4. General Pricing Assumptions
    • 9.4.5. Individual Drug Assumptions
    • 9.4.6. Generic Erosion
    • 9.4.7. Selection of Pipeline Agents
    • 9.4.8. Pricing of Pipeline Agents
  • 9.5. Physicians and Specialists Included in this Study
  • 9.6. Survey of Prescribing Physicians
  • 9.7. About the Authors
    • 9.7.1. Author
    • 9.7.2. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Contact Us
  • 9.10. Disclaimer

List of Tables

  • Table 1: Modes of HCV Transmission
  • Table 2: Symptoms of Acute and Chronic HCV Infection
  • Table 3: HCV Genotypes Present in the 9MM
  • Table 4: General Standard of Care by HCV Genotype
  • Table 5: Treatment Guidelines for HCV by Country
  • Table 6: Most-Prescribed Drugs for HCV by Class in the Global Markets, 2013
  • Table 7: Leading Treatments for HCV, 2012
  • Table 8: Product Profile - Incivek
  • Table 9: Efficacy of Incivek in Treatment-Naive Patients (ADVANCE Trial)
  • Table 10: Efficacy of Incivek in Treatment-Experienced Patients (REALIZE Trial)
  • Table 11: Common Incivek Adverse Drug Reactions
  • Table 12: Incivek SWOT Analysis, 2012
  • Table 13: Product Profile - Victrelis
  • Table 14: Victrelis Efficacy in Treatment-Naive Patients (SPRINT-2 Trial)
  • Table 15: Victrelis Efficacy in Treatment-Experienced Patients (RESPOND-2 Trial)
  • Table 16: Victrelis SWOT Analysis, 2012
  • Table 17: Product Profile - Pegasys
  • Table 18: Antiviral Efficacy of Peginterferon alfa-2a Compared with Interferon alfa-2b
  • Table 19: Pegasys SWOT Analysis, 2012
  • Table 20: Product Profile - PegIntron
  • Table 21: Antiviral Efficacy of Peginterferon alfa-2b Compared with Interferon alfa-2b
  • Table 22: PegIntron SWOT Analysis, 2012
  • Table 23: Effect of Addition of Ribavirin to Peginterferon HCV Therapy
  • Table 24: Ribavirin SWOT Analysis, 2012
  • Table 25: Summary of Minor Therapeutic Classes, 2012
  • Table 26: Overall Unmet Needs - Current Level of Attainment
  • Table 27: Clinical Unmet Needs - Gap Analysis, 2012
  • Table 28: HCV - Pipeline, 2012
  • Table 29: Comparison of Therapeutic Classes in Development for HCV, 2012
  • Table 30: Janssen's Simeprevir Ongoing Clinical Trials of Interest
  • Table 31: Product Profile - Simeprevir
  • Table 32: PILLAR Clinical Trial Results
  • Table 33: Adverse Events Observed in PILLAR Clinical Trial
  • Table 34: Simeprevir SWOT Analysis, 2012
  • Table 35: Boehringer Ingelheim's Faldaprevir Ongoing Clinical Trials of Interest
  • Table 36: Product Profile - Faldaprevir
  • Table 37: Efficacy of Interferon-Free Faldaprevir Regimen (SOUND-C2 Trial)
  • Table 38: Faldaprevir SWOT Analysis, 2012
  • Table 39: Bristol-Myers Squibb's Daclatasvir Ongoing Clinical Trials of Interest
  • Table 40: Product Profile - Daclatasvir
  • Table 41: Efficacy of Daclatasvir in Treatment-Naive Patients (COMMAND-1 Trial)
  • Table 42: Daclatasvir and Asunaprevir Quad Therapy Efficacy
  • Table 43: Daclatasvir Triple Therapy Adverse Events
  • Table 44: Daclatasvir SWOT Analysis, 2012
  • Table 45: Comparison of Peginterferon lambda with Peginterferon alfa (EMERGE Trial)
  • Table 46: Efficacy of Alisporivir in Treatment-Naive HCV GT2/3 Patients (VITAL-1 Trial)
  • Table 47: Sales Forecasts ($m) for HCV in Brazil, 2012-2022
  • Table 48: Key Events Impacting Sales for HCV in Brazil, 2012
  • Table 49: Brazilian HCV Market - Drivers and Barriers, 2012
  • Table 50: Physicians Surveyed, By Country

List of Figures

  • Figure 1: HCV Genome and Polyprotein Composition
  • Figure 2: HCV Lifecycle Overview
  • Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in HCV, 2012-2022
  • Figure 4: Sales for HCV Therapeutics in Brazil by Drug Class, 2012-2022
Back to Top